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Background: Bone fracture is one of the most common physical injuries in which gene expression and the
microenvironment are reprogramed to facilitate the recovery process.
Methods: By specific siRNA transfection and MTT assay, we evaluated the effects of metastasis-associated gene 1
(MTA1) in osteoblast growth. To show the role of MTA1 in osteoblast under hypoxia conditions, by overexpressing
and silencing MTA1 expression, we performed mineral deposition and alkaline phosphatase activity assay to observe
the differentiation status of osteoblast cells. Real-time PCR and Western blot assays were adopted to detect the
expression of certain target genes.
Results: Here, we reported that hypoxia-induced MTA1 expression through hypoxia-induced factor 1 alpha (HIF-1α)
and stimulated the growth of osteoblast MC3T3 cells. Silencing of MTA1 through specific siRNA suppressed MC3T3
cell growth and elicited cell differentiation and induced alkaline phosphatase activation and the upregulation of
bone morphogenetic protein-2 and osteocalcin.
Conclusions: We found that MTA1 was regulated by HIF-1α in hypoxia circumstance to suppress osteoblast
differentiation. These findings provide new insights for bone fracture healing and new strategies to develop
potential targets to promote fracture healing.
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Bone fracture is a prevalent medical condition that
occurs in a wide age range of individuals. Bone fracture
healing requires a certain period of time to rebuild its
structure and function. Fracture causes an urgent alter-
ation of the bone microenvironment, with a decrease in
blood supply and subsequent hypoxia. The healing pro-
cess of fractures starts when a hematoma forms surround-
ing the injured bone. However, the healing process of
fracture is promoted or hindered by several factors which
mainly affect the growth and differentiation of osteoblast
and the mineralization of the collagen matrix. Hypoxia is* Correspondence: jianruxiao83@163.com; 301wangyan@sina.com
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significantly influencing their healing process. A recent
study has demonstrated that fracture healing is delayed
under hypoxic conditions [1]. Hypoxia stimulates the ex-
pression of a variety of genes, including transcriptional
factors and cytokines [2]. Hypoxia-inducible factor (HIF)
family members are key molecules in the hypoxia-induced
network. Hypoxia induces vascular endothelial growth fac-
tor (VEGF) gene transcription in human osteoblast-like
cells through HIF-2α [3]. Hypoxia induced by fracture sig-
nificantly upregulates the expression of bone morpho-
genetic protein 2 (BMP-2), an osteogenic cytokine at the
fracture site, in the capillary endothelial cells [4,5]. It is
also suggested that endothelial cells may play a role in
stimulating MC3T3 cells through the potent osteogenic
factor BMP-2, other than in promoting angiogenesis.
Transcriptional responses to hypoxia are primarily
mediated by HIF-1, a heterodimer of HIF-1, and thes is an Open Access article distributed under the terms of the Creative Commons
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Loss of HIF-1 eliminates almost all oxygen-regulated
transcriptional responses [6]. Low oxygen tension-induced
HIF-1 expression promotes osteogenic growth and differ-
entiation, though its mechanism is not fully understood.
Metastasis tumor antigen 1 (MTA1) is a component of
the chromatin remodeling complex which influences
gene transcription by modulating the target gene chro-
matin [7]. MTA1 has been reported to be upregulated in
a series of carcinomas [8]. Overexpression of MTA1 in
cancer cells enhances cancer cell growth. Additionally,
MTA1 is also involved in the function of DNA damage
checkpoints [9] and anoikis [10]. It has been repor-
ted that MTA1 stabilizes HIF-1 by recruiting histone
deacetylase-1 [11]. However, whether MTA1 was regu-
lated by HIF-1 has never been illustrated. Moreover, the
biological function of MTA1 in osteoblast cells, especially
in bone fracture microenvironment, has not been repor-
ted. How MTA1 and HIF-1 interact with each other in the
context of fracture-associated hypoxia circumstances is to
be demonstrated.
In the present study, we analyzed the transcriptional
profiling after hypoxia stress in MC3T3 cells, and found
MTA1 was significantly upregulated. We further investi-
gated the possible role of MTA1 in the fracture healing
process and its mechanism.
Methods
Cell lines and culture conditions
The MC3T3 cell line was obtained from the American
Type Culture Collection (Manassas, VA, USA) and was
routinely maintained in α-modified Eagle’s Minimum
Essential Medium complete medium supplemented
with 10% fetal bovine serum (Gibco, Life Technologies,
Grand Island, NY, USA) before exposure to hypoxia. For
hypoxia treatment, cells were cultured at 37°C under 1%
O2 tension, with 95% N2 and 5% CO2 (Anaerobic System
PROOX model 110; BioSpherix Ltd., Lacona, NY, USA).
MTA1 plasmid and siRNA transfection
The MTA1 coding sequence was inserted into pCDH-
CMV-MCS-EF1-copGFP vector (pCDH-MTA1) by using
endonucleotases EcoRI and BamHI. The cloning primers
for MTA1 cDNA were as follows: forward primer: 5′-
AAAGAATTCATGGCCGCCAACATGTACA-3′; reverse
primer: 5′-AAAGGATCCCTAGTCCTCAATAACAATG
GGCTC-3′. Small interfering RNA targeting MTA1 was
designed and synthesized by Shanghai Gene Pharma
(Shanghai, China). The MTA1 siRNA sequences were 5′-
CTTGTGCCGTGAGATCCTAdTdT-3′ and 5′-GAACA
CGGCACTCTAGGATdTdT-3′. The control siRNA
sequences were 5′-GACTTCATAAGGCGCATdTdT-3′
and 5′-ATGCGCCTTATGAAGTCdTdT-3′. The MTA1
vector and siRNA were transfected with lipofectamine2000 (11668-019, Invitrogen, USA) as instructed by the
manual. Briefly, one day before transfection, the cells were
reseeded at 30% confluence; 24 hours later, for vector
DNA transfection, the complex was prepared using a
DNA (μg) to lipofectamine 2,000 (μL) ratio of 4 μg/6 μL,
while for siRNA transfection, the lipofectamine 2,000 and
siRNA complex was prepared using a RNA (μg) to lipofec-
tamine 2,000 (μL) ratio of 100 μg/8 μL. The complexes
were mixed into 0.5 mL serum-free culture medium for
15 minutes before being added into the cells.
Real time PCR
Total RNA isolated from treatment and ventricles of
MC3T3 cells were analyzed by real-time RT-PCR. All
samples were amplified in triplicates. One microgram of
RNA was used to reversely transcribe cDNA (Clontech,
Palo Alto, CA, USA). Relative quantification was
achieved by the comparative 2-ΔΔCt method. PCR reac-
tions were performed on an ABI PRISM 7900 HT Se-
quence Detection system with FastStart Universal SYBR
Green Master (Rox; Roche, Indianapolis, IN, USA) ac-
cording to the manufacturer’s instructions. The PCR
conditions were 95°C for 10 min followed by 40 cycles
of 95°C for 30 sec and 60°C for 60 sec. All samples were
run in triplicate and normalized to internal control
GAPDH (NM_001289726).
Western blot
Whole-cell protein extracts were prepared and quantified
by the Bicinchoninic Acid Protein Assay Kit (Pierce, Rock-
ford, IL, USA). Briefly, 100 μg of proteins were denatured,
separated on 12% SDS PolyAcrylamide Gel Electrophor-
esis gels, and transferred onto nitrocellulose membranes
(Bio-Rad, Waltham, MA, USA). The membranes were
probed with primary antibodies overnight at 4°C and incu-
bated with secondary horseradish peroxidase-conjugated
secondary antibodies for 1 h at room temperature. The
proteins were detected by enhanced chemoluminescence
(Applygen Technologies Inc., Beijing, China) and exposed
by autoradiography. To control protein loading, mem-
branes were stripped and reprobed with GAPDH antibody
(1:5,000). The primary antibodies included anti-osteocalcin
(1:1,500, AB10911, Millipore, Billerica, MA, USA), anti-
BMP-2 antibody (1:2,000, 18933-1-AP, Proteintech,
Chicago, IL, USA), anti-alkaline phosphatase antibody
(1:3,000, ab95462, Abcam, Cambridge, MA, USA), anti-
MTA1 antibody (1:1,000, ab71153, Abcam), and anti-
GAPDH antibody (G9545, Sigma, St. Louis, MO, USA).
The expression of proteins was quantified with Image J
software using actin as the internal control.
MTT assay
The adherent cells were transfected with MTA1-specific
siRNA, control siRNA, or MTA1-overexpressing vector,
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before they were seeded in a 96-well plate and incubated
for 4 days. The cell growth was evaluated every day.
Briefly, 100 μL of MTT (0.5 mg/mL final concentration)
was added and incubated in dark for an additional 4 h to
induce the production of formazan crystals at 37°C. The
supernatant was discarded. The formazan crystal was
dissolved in dimethyl sulfoxide. Cell viability was exam-
ined on a Microplate reader (Bio-rad, Model 680) at
570 nm excitatory emission wavelength. The cell viability
was plotted according to optical density values.
Mineral deposition
Overall, 5 × 103 MC3T3 cells were seeded into 6-well
plates coated with 0.1% gelatin and cultured in differenti-
ation medium consisting of α-minimal essential medium
(Invitrogen, USA) supplemented with 10% (v/v) fetal bo-
vine serum (Gibco), penicillin-streptomycin solution (with
final concentration of 500 unit/mL penicillin G sodium
and 500 mg/mL streptomycin sulfate; Invitrogen), 50 mg/
mL ascorbic acid (Sigma), vitamin C 50 μg/mL, 10 mM b-
glycerophosphate (Sigma), and 10 μmol/L dexamethasone
(Sigma). The media was changed every 3 days. Mineral de-
position was assessed by staining with alizarin-red. Briefly,
cells were washed once in PBS and fixed in phosphate-
buffered formalin for 20 min. Fixed cells were washed in
PBS and subsequently stained in 1% alizarin-red S (Sigma)
in distilled water for 15 min, then washed to remove
the remaining dye and air-dried. Images of stained
cells were captured using a light microscope (Leica,
Solms, Germany) and analyzed by appropriate image soft-
ware. Stained plates were photographed using a digital
camera. The numbers of bone nodules were counted
accordingly. Mineral deposition was also assessed by stain-
ing in alizarin-red after 14 days.
Alkaline phosphatase (ALP) activity assay
The ALP activity was assayed with Alkaline Phosphatase
Assay Kit (Colorimetric) from Abcam (ab83369). The
assay was performed following the manual instructions.
Briefly, 1 × 105 cells were homogenized in the assay buf-
fer, centrifuged at 13,000 g for 3 min to remove insoluble
material, and 80 μL of each sample were added into 96-
well plate and mixed with 50 μL 5 mM pNPP solution.
The plate was incubated for 60 minutes at 25°C in the
dark, until 20 μL stop solution was added into each well,
except to the background control. The standard curve
was also performed in this assay. The optical density
value was measured at 405 nm in a microplate reader.
Statistics
The differences in the results between groups were
compared using ANOVA or Student’s t-test. Results are
expressed as the means ± SD. SPSS 18.0 Statistical program(IBM SPSS, USA) was used for the statistical analysis. A
P value <0.05 was considered significant.
Results
Hypoxia up-regulates MTA1 expression
To examine the changes of gene profiling to hypoxia,
MC3T3 cells were treated with 1% oxygen (versus 20%
of control group), and the transcriptome analysis was
performed by microarray (Additional file 1). We obser-
ved that MTA1 was significantly upregulated in the low-
oxygen treated samples (data not shown). To verify the
upregulation of MTA1 by hypoxia in MC3T3 cells, we
performed real-time PCR and Western blot to check the
MTA1 expression at mRNA and protein levels. Results
showed that hypoxia at 1% oxygen tension significantly
upregulated MTA1 expression at both mRNA and pro-
tein levels (Figure 1).
Hypoxia upregulated MTA1 expression through HIF-1α
Hypoxia is a stress that can activate many signaling
pathways. HIF-1 is one of the key intermediate effectors
of hypoxia and translationally regulates the expression of
a series of downstream genes. To explore the possible
intermediate factor HIF-1 for regulating MTA1 response
to hypoxia, we transfected the MC3T3 cells with HIF-1
siRNA along with hypoxia treatment, we found that the
upregulation of MTA1 mRNA and protein was recov-
ered to the level comparable to control sample (Figure 2),
suggesting that HIF-1 is an activator of MTA1 expres-
sion under hypoxia.
Hypoxia-induced MTA1 expression stimulates the growth
of osteoblasts
To investigate the physiological role of MTA1 on the
proliferation of osteoblasts, we performed the growth
assay of MC3T3 cells under hypoxia combined with
MTA1 silencing or overexpression. MTA1 overexpression
significantly promoted MC3T3 cell growth (P <0.05),
while silencing of MTA1 inhibited the growth of MC3T3
osteoblast cells (P <0.05). Control siRNA did not alter the
growth of MC3T3 cells (P >0.05; Figure 3). These results
indicate that, upon hypoxia, MTA1 promotes the growth
of osteoblast cells.
Silencing of MTA1 stimulates osteoblast differentiation
Mineral deposition is an important step for the repair of
fractures, through which the structure and function of
bone are rebuilt. To further clarify the role of MTA1 in
osteoblast differentiation, we transfected the MC3T3
cells with MTA1-overexpressing plasmid pCDH-MTA1
or MTA1 siRNA. We found that overexpression of
MTA1 significantly slowed the mineralization of osteo-
blast MC3T3 cells, while MTA1 silencing accelerated
the process of mineralization (P <0.05; Figure 4). These
Figure 1 Hypoxia upregulated MTA1 expression. The MC3T3 cells were cultured under 1% oxygen tension (vs. 20% oxygen in the control).
The expressions of MTA1 mRNA (A) and protein (B) were evaluated by real-time and Western blot, respectively (n = 3).
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tiation of osteoblast cells. ALP is a key bone cell-specific
marker for osteoblast differentiation. MTA1 knockdown
significantly increased ALP activity, while MTA1 over-
expression decreased the activity of ALP, indicating aFigure 2 Hypoxia upregulated MTA1 expression through HIF-1.
(A) Silencing of HIF-1α reversed the hypoxia-induced MTA1 upregulation
at mRNA level (P <0.05). (B) Silencing of HIF-1 reversed the
hypoxia-induced MTA1 upregulation at protein level (n = 3).negative role of MTA1 in osteoblast differentiation
(Figure 5).
MTA1 alters the expression of osteocalcin, BMP-2, and
ALP proteins
To examine whether MTA1 activation upon hypoxia
altered the typical molecules involved in bone mature
and repair, such as osteocalcin and BMP-2, we detected
the protein levels of these molecules by Western blot.
Results showed that both osteocalcin and BMP-2 were
downregulated by MTA1, while they were upregulated
by specific siRNA against MTA1 (Figure 6). Consistent
with ALP activity assay, ALP protein level was upre-
gulated by MTA1 siRNA but downregulated by MTA1
overexpression (Figure 6).
Discussion
Bone fractures are one of the most frequent events
occurring in all sectors of the population, from kids toFigure 3 Hypoxia-induced MTA1 promoted the growth of
MC3T3 cells. MC3T3 cells were transfected with pCDH-MTA1, MTA1
siRNA, or control siRNA. The growth of MC3T3 cells was evaluated
by MTT assay. MTA1 OE, MTA1 overexpression. P <0.05 was considered
statistically significant (n = 3).
Figure 4 Silencing of MTA1 slowed the mineralization of
osteoblasts. (A) Phase-contrast microscopic images of MC3T3 cells
cultured in differentiation medium after overexpression or silencing
of MTA1 (×100). MTA1 OE, MTA1 overexpression. (B) The quantitative
analysis of bone nodules after MTA1 manipulation (n = 3).
Figure 5 ALP activity assay in MC3T3 cells after MTA1
knockdown or overexpression. The ALP activity was assayed with
Alkaline Phosphatase Assay Kit following the instructions. MTA1 OE,
MTA1 overexpression (n = 3).
Figure 6 MTA1 regulated the expression of osteocalcin, BMP-2,
and ALP. MC3T3 cells were transfected with pCDH-MTA1, MTA1
siRNA, or control siRNA. Null vector and control siRNA were used as
controls. The expression of osteocalcin, BMP-2, and ALP was examined
by Western blot assay. MTA1 OE, MTA1 overexpression (n = 3).
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tures is affected by a variety of factors, including the
blood supply, oxygen concentration, and various inflam-
matory factors [12].
Hypoxia induced by blood supply shut-off is the main
feature of a fracture, thus initiating many downstream cas-
cades. The HIF family is one of those upstream signaling
commanders. HIF-1 is a key player in hypoxia-induced
physiological and pathological processes, especially in
bone fractures [13]. HIF-1 is activated by hypoxia at the
earliest stage of fracture and plays a positive role in the
promoting the healing of bone fracture. HIF-1 is able to
mediate the hypoxic-stimuli-induced expression of
VEGF in MC3T3 cells [14]. The induction of VEGF in
fracture conditions contributes to the re-establishment
of the blood supply and hence the structure remodeling
of bone.MTA1 has been mostly studied in cancer [15,16].
MTA1 protein contributes to the process of cancer
progression and metastasis through multiple genes and
protein targets and interacting proteins with roles in
transformation, anchorage-independent growth, invasion,
survival, DNA repair, angiogenesis, hormone independ-
ence, metastasis, and therapeutic resistance [17-19]. It has
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through the Wnt pathway, which is a key knot in the
stemness regulation network. Prominently, MTA1 en-
hances the ability of cancer cell invasion and metastasis
in breast cancer and some other cancers. In estrogen
receptor-positive breast cancer cells, MTA1 suppresses
the estrogen-receptor element-driven transcription and
disrupts estradiol responsiveness, thus contributing to
progression of breast cancer to more invasive pheno-
types [7]. Targeting MTA1 in the prostate blocks cancer
angiogenesis [16]. As for its correlation with hypoxia
conditions, it has been reported that MTA1 stabilizes
HIF-1 by recruiting histone deacetylase 1, resulting in
angiogenesis [20]. It is unclear whether HIF-1 has some
effects on MTA1. In the current study, we found that
HIF-1, as a key responder to hypoxia, is able to induce
the expression of MTA1. It is the first report indicating
that MTA1 may be involved in the healing process of
bone fractures. We assessed the effects of HIF-1-
induced MTA1 expression on biological behaviors of
MC3T3 cells and found that the hypoxia-induced
MTA1 upregulation had a positive effect on the healing
process of bone fractures at the early stage of fracture.
MTA1 promoted the growth of MC3T3 cells under hyp-
oxia (Figure 7). The promotion of osteoblast growth by
MTA1 under the hypoxic microenvironment after bone
fracture is a necessary response heading to fracture
healing. Moreover, assays by mineral deposition and
ALP activity verified a suppressive role of MTA1 over-
expression in osteoblast differentiation. The delayed dif-
ferentiation of MC3T3 cells by MTA1 upregulation may
promise an active proliferating osteoblast population to
support the healing process. Nevertheless, the actual
role of MTA1 should be verified in human osteoblasts.Figure 7 A schematic presentation showing the signaling
pathway from fracture-induced hypoxia to MTA1 upregulation,
suppressing osteoblast differentiation.Bone mineralization is regulated by a number of fac-
tors including osteocalcin, BMP-2, and ALP. We also
detected the molecules involved in the fracture healing
process after MTA1 manipulation. BMP-2 and osteocal-
cin are important molecules involved in bone repair. In
MC3T3 cells, HIF-1 is able to upregulate BMP-2 [21]
and downregulate osteocalcin [22]. The suppression of
osteocalcin leads to a delay of osteoblast mineralization
and differentiation. We found that HIF-1-mediated MTA1
expression suppressed osteocalcin expression under hyp-
oxic conditions. ALP is a key enzyme in the process of
biomineralization, inducing the mineralization of collagen
sheets in the fracture. In our study, we found overex-
pressed MTA1 reduced ALP activity and that MTA1
knockdown resulted in increased ALP activity. Therefore,
it is reasonable to propose roles of MTA1 in stimulating
osteoblast growth but suppressing osteoblast differenti-
ation at the early stage of bone fracture.Conclusions
It has been reported that HIF-1 is able to induce self-
renewal and growth factor secretion of multipotential
stromal cells under hypoxic conditions [23]. In the current
study, we found that, under hypoxic conditions, the HIF-
1/MTA1 pathway promoted osteoblast growth but sup-
pressed the differentiation of MC3T3 cells, keeping the
cells in a self-renewal potentiated status. This may help to
accumulate more osteoblast cells at the early stage of frac-
ture for the repair and re-construction of bone. However,
the potential role of MTA1 in bone fracture healing needs
to be verified in in vivo models.Additional file
Additional file 1: Microarray data from MC3T3 after HIF-1α silencing
under hypoxia condition.Abbreviations
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